What are RBC-transfusion-dependence and -independence?

Leukemia Research

Volumn 35, Issue 1, 2011, Pages 8-11

  Gale, R P ^a   Barosi, G ^b   Barbui, T ^c   Cervantes, F ^d   Dohner, K ^e   Dupriez, B ^f   Gupta, V ^g   Harrison, C ^h   Hoffman, R ⁱ   Kiladjian, J J ^j   Mesa, R ^k   Mc Mullin, M F ^l   Passamonti, F ^m   Ribrag, V ⁿ   Roboz, G ^o   Saglio, G ^p   Vannucchi, A ^q   Verstovsek, S ^r  

^a IMPERIAL COLLEGE LONDON   (United Kingdom)

^b UNIVERSITY OF PAVIA   (Italy)

^c OSPEDALI RIUNITI   (Italy)

^d HOSPITAL CLÍNIC   (Spain)

^e UNIVERSITY OF ULM   (Germany)

^f Centre Hospitalier de LENS   (France)

^g UNIVERSITY OF TORONTO   (Canada)

^h GUY'S AND ST THOMAS' NHS FOUNDATION TRUST   (United Kingdom)

ⁱ MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^j SAINT LOUIS HOSPITAL   (France)

^k MAYO CLINIC   (United States)

^l QUEEN'S UNIVERSITY BELFAST   (United Kingdom)

^m UNIVERSITY OF PAVIA   (Italy)

ⁿ INSTITUT GUSTAVE ROUSSY   (France)

^o WEILL CORNELL MEDICAL COLLEGE   (United States)

^p UNIVERSITY OF TURIN   (Italy)

^q UNIVERSITY OF FLORENCE   (Italy)

^r UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

more..

Author keywords

Anemia; Anemia therapy; Aplastic anemia; Myelodysplastic syndrome; Myeloproliferative neoplasm; Paroxysmal nocturnal hemoglobinuria; RBC transfusions

Indexed keywords

ANEMIA; DISEASE SEVERITY; E-MAIL; ERYTHROCYTE TRANSFUSION; ERYTHROCYTE TRANSFUSION DEPENDENCE; ERYTHROCYTE TRANSFUSION INDEPENDENCE; ERYTHROPOIESIS; HUMAN; LETTER; MEDICAL SPECIALIST; PRIORITY JOURNAL; QUESTIONNAIRE; SURVIVAL;

EID: 78650172358     PISSN: 01452126     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.leukres.2010.07.015     Document Type: Letter

References (29)

1. Jadersten M., Malcovati L., Dybedal I., et al. Erythropoietin and granulocyte-colony stimulating factor treatment associated with improved survival in myelodysplastic syndrome. J Clin Oncol 2008, 26:3607-3613.
2. Park S., Grabar S., Kelaidi C., et al. Predictive factors of response and survival in myelodysplastic syndrome treated with erythropoietin and G-CSF: the GFM experience. Blood 2008, 111:574-582.
3. Hellstrom-Lindberg E., Gulbrandsen N., Lindberg G., et al. A validated decision model for treating the anaemia of myelodysplastic syndromes with erythropoietin+granulocyte colony-stimulating factor: significant effects on quality of life. Br J Haematol 2003, 120:1037-1046.
4. Palmer S.C., Navaneethan S.D., Craig J.C., et al. Meta-analysis: erythropoiesis-stimulating agents in patients with chronic kidney disease. Ann Intern Med 2010, 153:23-33.
5. Rizzo J.D., Somerfield M.R., Hagerty K.L., et al. Use of epoetin and darbepoetin in patients with cancer: 2007 American Society of Clinical Oncology/American Society of Hematology 2007 clinical practice guideline update. J Clin Oncol 2008, 1:132-149.
6. Malcovati G., Germin U., Kuendgen A., et al. Time dependent prognostic scoring system for predicting survival and leukemic evolution in myelodysplastic syndromes. J Clin Oncol 2007, 25:3503-3510.
7. Cheson B.D., Greenberg P.L., Bennett J.M., et al. Clinical application and proposal for modification of the International Working Group (IWG) response criteria in myelodysplasia. Blood 2006, 108:419-425.
8. Silverman L.R., McKenzie D.R., Peterson B.L., et al. Further analysis of trials with azacitidine in patients with myelodysplastic syndrome: studies 8421, 8921, and 9221 by the Cancer and Leukemia Group B. J Clin Oncol 2006, 24:3895-3903.
9. Lyons R.M., Cosgriff T.M., Modi S.S., et al. Hematologic response to three alternative dosing schedules of azacitidine in patients with myelodysplastic syndromes. J Clin Oncol 2009, 27:1850-1856.
10. Cermak J., Kacirkova P., Mikulenkova D., et al. Impact of transfusion dependency on survival in patients with early myelodysplastic syndrome without excess of blasts. Leuk Res 2009, 33:1469-1474.
11. Tefferi A., Barosi G., Mesa R.A., et al. IWG for Myelofibrosis Research and Treatment (IWG-MRT) International Working Group (IWG) consensus criteria for treatment response in myelofibrosis with myeloid metaplasia, for the IWG for Myelofibrosis Research and Treatment (IWG-MRT). Blood 2006, 108:1497-1503.
12. Tefferi A., Siragusa S., Hussein K., et al. Transfusion at presentation and its acquisition in the first year of diagnosis are both equally detrimental for survival in primary myelofibrosis - prognostic relevance is independent of IPSS or karyotype. Am J Hematol 2010, 85:14-17.
13. Tefferi A. JAK2 mutations and clinical practice in myeloproliferative neoplasms. Cancer J 2007, 13:366-371.
14. Cervantes F., Dupriez B., Pereira A., et al. New prognostic scoring system for primary myelofibrosis based on a study of the International Working Group for Myelofibrosis Research and Treatment. Blood 2009, 26(113):2895-2901.
15. Passamonti F., Cervantes F., Vannucchi A.M., et al. A dynamic prognostic model to predict survival in primary myelofibrosis: a study by the IWG-MRT (International Working Group for Myeloproliferative Neoplasms Research and Treatment). Blood 2010, 115(9):1703-1708.
16. Porter J., Galanello R., Saglio G., et al. Relative response of patient with myelodysplastic syndromes and other transfusion-dependent anaemias to deferasirox (ICL670): a 1-yr prospective study. Eur J Haematol 2008, 80:168-176.
17. Hillmen P., Young N.S., Schubert J., et al. The complement inhibitor eculizumab in paroxysmal nocturnal hemoglobinuaria. N Engl J Med 2006, 355:1233-1243.
18. Hill A., Hillmen P., Richards S.J., et al. Sustained response and long-term safety of eculizumab in paroxysmal nocturnal hemoglobinuria. Blood 2005, 106:2559-2565.
19. Hillmen P., Hall C., Marsh J.C., et al. Effect of eculizumab on hemolysis and transfusion requirements in patients with paroxysmal nocturnal hemoglobinuria. N Engl J Med 2004, 350:552-559.
20. Cheson B.D., Greenberg P.L., Bennett J., et al. Clinical application and proposal for modification of the International Working Group (IWG) response criteria in myelodysplasia. Blood 2006, 108:419-425.
21. Shekelle P.G., Kahan J.P., Bernstein S.J., et al. Reproducibility of the method to identify the overuse and underuse of medical procedures. N Engl J Med 1998, 388:1988-1995.
22. Winslow C.M., Solomom D.H., Chassin M.R., et al. The appropriateness of carotid endartectomy. N Engl J Med 1988, 318:721-727.
23. Park R.E., Fink A., Brook R.H., et al. Physician ratings of appropriate indications for six medical and surgical procedures. Am J Pub Health 1986, 76:766-772.
24. Brook R.H. The RAND/UCLA appropriateness method. Clinical practice guideline development: methodology perspectives 1994, US Department of Health and Human Services, Public Health Service, Agency for Health Care Policy and Research, Office of the Forum for Quality and Effectiveness in Health Care, Rockville, MD, [Pub. No. 95-0009; also available as Brook RH. The Rand/UCLA appropriateness method: Rand/RP-395. Santa Monica, CA: Rand Corporation, 59-70]. K.A. McCormick, S.R. Moore, R.A. Siegel (Eds.).
25. Merrick N.J., Fink A., Park R.E., et al. Derivation of clinical indications for carotid endarterectomy by an expert panel. Am J Pub Health 1987, 77:187-190.
26. Shekelle P.G., Chassin M.R., Park R.E. Assessing the predictive validity of the RAND/UCLA appropriateness method criteria for performing carotid endarterectomy. Intl J Tech Assess Health Care 1998, 14:707-727.
27. Shelby J.V.B., Fireman B.H., Lundstrom R.J., et al. Variation among hospitals in coronary-angiography practices and outcomes after myocardinal infarction in a large health maintenance organization. N Engl J Med 1996, 335:1888-1896.
28. Kravitz R.L., Laouri M., Kahan J.P., et al. Validity of criteria used for detecting underuse of coronary revascularization. J Am Med Assoc 1995, 274:632-638.
29. Gale R.P., Park R.E., Dubois R., Bitran J., Buzdar A., Hortobagyi G., et al. Delphi-consensus panel analysis of appropriateness of high-dose chemotherapy and blood cell or bone marrow autotransplants in women with breast cancer. Clin Transplant 2000, 14:32-41.